Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Avacopan for the Treatment of ANCA-Associated Vasculitis

(2021) David R.W. Jayne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers

(2020) Simon A. Carter et al.   Clinical Journal of the American Society of Nephrology

C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh–/– Cfd–/– mice

(2020) Yuzhou Zhang et al.   JCI Insight

Clinical use of complement, inflammation and fibrosis biomarkers in autoimmune glomerulonephritis.

(2020) Myriam Khalili et al.   Kidney International Reports

Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project

(2020) Katherine R. Tuttle et al.   Clinical Journal of the American Society of Nephrology

Complement-mediated kidney diseases

(2020) Felix Poppelaars et al.   MOLECULAR IMMUNOLOGY

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

(2019) Aliza Thompson et al.   Clinical Journal of the American Society of Nephrology

Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis

(2019) Hannah R. Wilson et al.   KIDNEY INTERNATIONAL

C3 glomerulopathy — understanding a rare complement-driven renal disease

(2019) Richard J. H. Smith et al.   Nature Reviews Nephrology

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis

(2019) Gérard Socié et al.   BRITISH JOURNAL OF HAEMATOLOGY

Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease

(2019) Simon A. Carter et al.   KIDNEY INTERNATIONAL

Clinical promise of next-generation complement therapeutics

(2019) Dimitrios C. Mastellos et al.   NATURE REVIEWS DRUG DISCOVERY

Measured and estimated glomerular filtration rate: current status and future directions

(2019) Andrew S. Levey et al.   Nature Reviews Nephrology

Kidney disease trials for the 21st century: innovations in design and conduct

(2019) William G. Herrington et al.   Nature Reviews Nephrology

Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy

(2018) Moglie Le Quintrec et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Life-long antimicrobial therapy: where is the evidence?

(2018) Jillian S Y Lau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy

(2018) Andrew S. Bomback et al.   KIDNEY INTERNATIONAL

Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices

(2018) Ingeborg M. Bajema et al.   KIDNEY INTERNATIONAL

Back to the future – non-canonical functions of complement

(2018) Claudia Kemper et al.   SEMINARS IN IMMUNOLOGY

Diagnosis and management of PNH: review and recommendations from a Belgian expert panel

(2018) T Devos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Estimated GFR: time for a critical appraisal

(2018) Esteban Porrini et al.   Nature Reviews Nephrology

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

(2018) Kioa L. Wijnsma et al.   PEDIATRIC NEPHROLOGY

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

(2017) Hernán Trimarchi et al.   KIDNEY INTERNATIONAL

Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation

(2016) Kristina N. Ekdahl et al.   IMMUNOLOGICAL REVIEWS

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy

(2015) A. Thompson et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy

(2015) M. M. Ruseva et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

(2015) Richard J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the Complement Biomarker Profile of C3 Glomerulopathy

(2014) Y. Zhang et al.   Clinical Journal of the American Society of Nephrology

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

(2014) Rosanna Coppo et al.   KIDNEY INTERNATIONAL

Eculizumab hepatotoxicity in pediatric aHUS

(2014) Wesley Hayes et al.   PEDIATRIC NEPHROLOGY

Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2013) Ronald D. Perrone et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Pathology after Eculizumab in Dense Deposit Disease and C3 GN

(2012) L. C. Herlitz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Loss of Properdin Exacerbates C3 Glomerulopathy Resulting from Factor H Deficiency

(2012) M. M. Ruseva et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

(2012) Jun Yuan et al.   ARTHRITIS RESEARCH & THERAPY

Histopathologic Classification of ANCA-Associated Glomerulonephritis

(2010) A. E. Berden et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Early Elevations of the Complement Activation Fragment C3a and Adverse Pregnancy Outcomes

(2010) Anne M. Lynch et al.   OBSTETRICS AND GYNECOLOGY

Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T Cells

(2008) Michael G. Strainic et al.   IMMUNITY